Pregabalin
Product Images NDC 55700-805

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 55700-805). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

557000804

Pregabalin 50 mg capsule label from Quality Care Products, LLC. The label shows a 30-capsule package with the NDC 55700-804-30 and GTIN 00355700804305. It includes storage instructions to store at 77 degrees F, a habit-forming warning, and notes that the product is Rx only. The manufacturer is listed as ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

557000805

Label for Pregabalin 75 mg capsules, containing 30 capsules. The label indicates the product is distributed by Quality Care Products, LLC, with manufacturing by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. It includes storage instructions, a habit-forming warning, the NDC 55700-805-30, and a barcode on the right side.*

FDA Label Image

557000817

Pregabalin 100 mg capsules label packaged and distributed by Quality Care Products, LLC. The label indicates a package size of 30 capsules, contains a C V control symbol, and is marked Rx only. It includes storage instructions to store at 77 degrees F and warnings that the drug may be habit-forming and should be kept out of reach of children. The label also lists the NDC 55700-817-30 and states the drug is manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

557000891

Label for Pregabalin 150 mg capsules distributed by Quality Care Products, LLC, with a package size of 60 capsules. The label includes storage information, a warning that the drug may be habit-forming, an NDC number 55700-891-60, and indicates Rx only. Manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY. The label also advises keeping medication out of reach of children.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, along with a placebo group, with lines distinguished by different patterns. The x-axis is percent improvement in pain from baseline and the y-axis is percent of patients improved.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows higher patient improvement percentages with Pregabalin compared to placebo across increasing pain improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved as a function of percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day compared to placebo. Pregabalin 300 mg two times a day shows the highest improvement, followed by 150 mg, 75 mg, and placebo with the lowest improvement rates.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting percent improvement in pain from baseline versus the percent of patients improved. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing higher improvement percentages for both Pregabalin dosages compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows curves demonstrating patient improvement percentages across different pain improvement thresholds.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar chart titled Study E1 and Study E3 shows responder rates (%) for different doses of Pregabalin compared to placebo. Study E1 dose groups include 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day with BID dosing. Study E3 shows doses 300 mg/day BID and 600 mg/day TID. Responder rates increase with dose, reaching up to 51% in Study E1 and 49% in Study E3, with statistical significance indicated versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph illustrating seizure reduction (median percentage change from baseline) plotted against dose in mg/day. The graph compares data from four different studies labeled as Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID, with significance values indicated for several data points. Dose ranges from 0 to 600 mg/day, and seizure reduction varies up to about 60%. A note states dose=placebo and only significant p-values are shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares Pregabalin daily doses of 300 mg, 450 mg, 800 mg, and a placebo, with separate lines representing each treatment group's patient improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing Pregabalin and placebo over 180 days showing the estimated percentage of subjects without LTR. The y-axis represents the estimated percentage from 0% to 100%, and the x-axis shows time in days. The Pregabalin group decline is less steep than placebo, indicating higher percentages of subjects without LTR over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 using BOCF analysis. The x-axis shows percent improvement from 0 to 100, while the y-axis shows the percent of subjects improved. Two lines represent Pregabalin and Placebo groups, with Pregabalin showing higher improvement percentages across the range. The chart is related to Pregabalin, labeled by Quality Care Products, LLC.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 16, showing two curves labeled Pregabalin (solid line) and Placebo (dashed line). The y-axis represents percent of subjects improved, and the x-axis represents percent improved from baseline to week 16 BOCF, with vertical lines marked at 30, 50, and 70 percent improvements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.